EP2881739B1 - Method and kit for determining the genome integrity and/or the quality of a library of dna sequences obtained by deterministic restriction site whole genome amplification - Google Patents
Method and kit for determining the genome integrity and/or the quality of a library of dna sequences obtained by deterministic restriction site whole genome amplification Download PDFInfo
- Publication number
- EP2881739B1 EP2881739B1 EP13195770.6A EP13195770A EP2881739B1 EP 2881739 B1 EP2881739 B1 EP 2881739B1 EP 13195770 A EP13195770 A EP 13195770A EP 2881739 B1 EP2881739 B1 EP 2881739B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- library
- genome
- primer pair
- pcr
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims description 49
- 238000000034 method Methods 0.000 title claims description 27
- 238000013412 genome amplification Methods 0.000 title claims description 13
- 108020004414 DNA Proteins 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 48
- 241000282414 Homo sapiens Species 0.000 claims description 46
- 238000003556 assay Methods 0.000 claims description 38
- 210000000349 chromosome Anatomy 0.000 claims description 19
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 claims description 14
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 14
- 230000003321 amplification Effects 0.000 claims description 13
- 230000031864 metaphase Effects 0.000 claims description 13
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 13
- 238000004458 analytical method Methods 0.000 claims description 12
- 238000009396 hybridization Methods 0.000 claims description 9
- 238000007480 sanger sequencing Methods 0.000 claims description 9
- 230000000052 comparative effect Effects 0.000 claims description 7
- 108091008109 Pseudogenes Proteins 0.000 claims description 6
- 102000057361 Pseudogenes Human genes 0.000 claims description 6
- 238000012252 genetic analysis Methods 0.000 claims description 6
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 108700024394 Exon Proteins 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 3
- 230000004544 DNA amplification Effects 0.000 claims description 3
- 101150105104 Kras gene Proteins 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 description 21
- 238000003752 polymerase chain reaction Methods 0.000 description 19
- 210000005266 circulating tumour cell Anatomy 0.000 description 13
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 12
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 12
- 210000000481 breast Anatomy 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 238000007837 multiplex assay Methods 0.000 description 12
- 108091093088 Amplicon Proteins 0.000 description 10
- 210000002307 prostate Anatomy 0.000 description 10
- 102100030708 GTPase KRas Human genes 0.000 description 8
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000001840 diploid cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 101001094028 Homo sapiens Phosphatase and actin regulator 2 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100035266 Phosphatase and actin regulator 2 Human genes 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000002358 circulating endothelial cell Anatomy 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007479 molecular analysis Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 230000000970 DNA cross-linking effect Effects 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003313 haploid nucleated cell Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000026727 thymocyte apoptotic process Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000000143 trophectoderm cell Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
- C12Q2535/122—Massive parallel sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2545/00—Reactions characterised by their quantitative nature
- C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
- C12Q2545/101—Reactions characterised by their quantitative nature the purpose being quantitative analysis with an internal standard/control
Definitions
- the present invention relates to a method and a kit for determining the integrity of the genome of a sample, in particular a single cell, and/or the quality of a library of DNA sequences obtained by deterministic restriction site whole genome amplification (DRS-WGA) of the genome of the sample.
- DRS-WGA deterministic restriction site whole genome amplification
- WGA Whole Genome Amplification
- CTC single circulating tumour cells
- CTCs have been described as being frequently apoptotic ( Mehes, G., et al., Circulating breast cancer cells are frequently apoptotic. Am J Pathol, 2001. 159 (1) : p.17-20 ).
- genomic DNA is fragmented into small pieces of 180 bp to 200 bp length ( Wyllie, AH., Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature, 1980. 284(5756): p.555-6 ).
- Genome Integrity status of a single cell it is thus important to assess the Genome Integrity status of a single cell, as this can be linked to the biological status of the cell itself, and give clinically relevant information on the overall status of a cancer patient, which goes beyond the information provided by just counting the CTCs and complements the molecular characterization of those CTCs.
- DNA crosslinking and/or fragmentation occur with chemical treatment (e.g. fixation) applied on patient-derived cells and tissues for needed sample conservation after biopsy.
- chemical treatment e.g. fixation
- Available single cell WGA kits assess quality of whole genome amplification by measuring the concentration of the WGA product only.
- protocols for these methods include at least one random step during the procedure of single cell DNA amplification, specific assays to evaluate genome integrity of the input sample (in general a single cell) such as apoptotic or non-apoptotic status, or the quality of the output of the WGA product, such as the suitability for further genetic analysis, are difficult.
- DRS-WGA deterministic restriction site whole genome amplification
- DRS-WGA has been shown to be better for the amplification of single cells (see for example: Lee YS, et al: Comparison of whole genome amplification methods for further quantitative analysis with microarray-based comparative genomic hybridization. Taiwan J Obstet Gynecol. 2008, 47(1):32-41 ) and also more tolerant to DNA degradation due to fixative treatment (see for example: Stoecklein N.H. et al: SCOMP is Superior to Degenerated Oligonucleotide Primed-PCR for Global Amplification of Minute Amounts of DNA from Microdissected Archival Samples. American Journal of Pathology 2002, Vol. 161, No. 1 ; Arneson N. et al.: Comparison of Whole Genome Amplification methods for analysis of DNA extracted from microdissected early breast lesions in formalin-fixed paraffin-embedded tissue. ISRN Oncol. 2012; 2012;710692 ).
- An object of the present invention is therefore to provide a method for determining the integrity of the genome of a sample and/or the quality of a library of DNA sequences obtained by DRS-WGA that provides robust and reliable results and allows in particular to predict the performance of molecular assays downstream of the DRS-WGA.
- sample there is intended a sample comprising at least one particle of a biological entity, said particle comprising at least a DNA sequence representing the genome or a substantial subset of the genome of that biological entity.
- Said entity is a human, said at least one particle may be a single cell, or a single-cell nucleus, or a haploid germ cell, or a chromosome.
- genome there is intended the entire genome or said substantial subset of the genome.
- quality of a library of DNA sequences there is intended the suitability of the library of DNA sequences to be used for the genetic characterization of certain features such as, by way of non-limiting example, the presence of point mutations, deletions, insertions, copy number variations.
- the method according to the present invention for determining the integrity of the genome of a sample and/or the quality of a library of DNA sequences obtained by deterministic restriction site whole genome amplification (DRS-WGA) of the genome of the sample comprises steps (a) to (d) of claim 1.
- DRS-WGA deterministic restriction site whole genome amplification
- the sample may preferably be a circulating tumour cell (CTC), a circulating fetal cell, a circulating endothelial cell (CEC), an oocyte, a cumulus cell, a sperm, a blastomere, or a trophectoderm cell.
- CTC circulating tumour cell
- CEC circulating endothelial cell
- oocyte a cumulus cell
- sperm a sperm
- blastomere a trophectoderm cell
- step (a) the library of DNA sequences is provided.
- step (b) the library of DNA sequences is amplified by PCR using at least one first primer pair which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp, preferably from 1000 bp to 2000 bp, and corresponding to a sequence of the genome located on a first chromosome arm, the step of amplifying giving rise to a first PCR product from 50 bp to 1000 bp.
- the DNA sequence of the library to which the first primer pair hybridises encompasses the D5S2117 region of chromosome 5q.
- the forward primer of the first primer pair is SEQ ID NO:4 and the reverse primer of the first primer pair is SEQ ID NO:3.
- step (c) the first PCR product is detected.
- Agarose gel electrophoresis may be used to separate and detect the PCR product as well as other methods known in the art.
- step (d) the presence of the first PCR product is correlated with the integrity of the genome of the sample and/or the quality of the library of DNA sequences.
- step (b) at least one second primer pair is used which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp, more preferably from 1000 bp to 2000 bp, and corresponding to a sequence of the genome located on a second chromosome arm other than the first chromosome arm, the step of amplifying giving rise to a second PCR product from 50 bp to 1000 bp having a size other than the first PCR product.
- Step (b) uses at least one second primer pair, the second PCR product is also detected in step (c) and the presence of the second PCR product is also correlated with the integrity of the genome of the sample and/or the quality of the library of DNA sequences in step (d).
- the DNA sequence of the library to which the second primer pair hybridises encompasses exons 2 and 3 of the TRP53 gene.
- the forward primer of the second primer pair is SEQ ID NO:6 and the reverse primer of second primer pair is SEQ ID NO:5.
- step (b) at least one third primer pair is used which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp, more preferably from 1000 bp to 2000 bp, and corresponding to a sequence of the genome located on a third chromosome arm other than the first and second chromosome arms, the step of amplifying giving rise to a third PCR product from 50 bp to 1000 bp having a size other than the first and second PCR products.
- Step (b) uses at least one third primer pair, the third PCR product is also detected in step (c) and the presence of the third PCR product is also correlated with the integrity of the genome of the sample and/or the quality of the library of DNA sequences in step (d).
- the DNA sequence of the library to which the third primer pair hybridises encompasses the KRT19 pseudo-gene 1 (indicated for short as CK19).
- the forward primer of the third primer pair is SEQ ID NO:8 and the reverse primer of the third primer pair is SEQ ID NO:7.
- step (b) at least one fourth primer pair is used which hybridises to a DNA sequence of the library having a length from 80 bp to 300 bp, the step of amplifying giving rise to a fourth PCR product from 50 bp to 200 bp having a size other than the first, the second and the third PCR products.
- step (b) uses at least one fourth primer pair
- the fourth PCR product is also detected in step (c) and the presence of the fourth PCR product is also correlated with the integrity of the genome of the sample and/or the quality of the library of DNA sequences in step (d).
- the DNA sequence of the library to which the fourth primer pair hybridises encompasses codons 12 and 13 of the KRAS gene.
- the forward primer of the fourth primer pair is SEQ ID NO:17 and the reverse primer of the fourth primer pair is SEQ ID NO:18.
- kits for determining the integrity of the genome of a sample and/or the quality of a library of DNA sequences obtained by deterministic restriction site whole genome amplification (DRS-WGA) of the genome of the sample comprising at least one of:
- the kit comprises the first, second and third primer pairs.
- the kit further comprises at least one fourth primer pair which hybridises to a DNA sequence of the library having a length from 80 bp to 300 bp, wherein the first, second, third and fourth primer pairs give rise, when amplified by PCR, to PCR products having different size from one another.
- the kit comprises the first, second, third and fourth primer pairs.
- the kit may be used for predicting the success of a genetic analysis assay after amplification of single cell genomic DNA by DRS-WGA.
- the genetic analysis assay is Sanger sequencing for mutation analysis, assessment of specific copy number changes, quantitative PCR for gene amplification, metaphase Comparative Genomic Hybridisation (CGH), or array Comparative Genomic Hybridisation (CGH).
- samples with at least 1-2 out of 4 PCR products can be used. Positivity to at least 3 out of 4 PCR products is predictive of successful genome-wide analysis with metaphase CGH. For array CGH it is advisable to use samples with 4 out of 4 positive PCR products.
- PCR products are also referred to as “markers” and PCR amplification reactions including several primer pairs are also referred to as "multiplex assays”.
- PCR amplification reactions including several primer pairs designed to determine the integrity of the genome of a sample and/or the quality of the library of DNA sequences obtained by deterministic restriction site whole genome amplification (DRS-WGA) of the genome of the sample are also referred to as “quality control assays” or “QC assays”.
- DRS-WGA deterministic restriction site whole genome amplification
- CGH metaphase comparative genomic hybridization
- Step 1 94.0°C 2 min Step 2 Annealing Temp 30 s Step 3 72.0°C 2 min Step 4 94.0°C 15 s Step 5 Annealing Temp 30 s Step 6 72.0°C 20 s 14 additional cycles (steps 4-6) Step 7 94.0°C 15 s Step 8 Annealing Temp 30 s Step 9 72.0°C 30 s 24 additional cycles (steps 7-9) Step 10 72.0°C 2 min Step 11 4°C forever Table 1.
- PCR markers 72 single cell genomes from different types of human cancers (24 breast disseminated cancer cells (DCCs) 24 prostate DCCs, 24 melanoma DCCs) were re-amplified. For each of the three groups, 12 cells were included which resulted in successful metaphase hybridization in a previous CGH experiment and 12 cells which resulted in a failed metaphase hybridization in a previous CGH experiment. Specific PCRs for all selected markers were performed and the assay was evaluated for accuracy in predicting the outcome of metaphase CGH.
- DCCs breast disseminated cancer cells
- 24 melanoma DCCs 24 melanoma DCCs
- PCRs on the long Mse-fragments D5S2117, TRP53-Ex2/3 and KRT19 pseudogene 1 provided best separation between amplified genomes with successful and failed metaphase CGH.
- An assay of these three fragments showed high assay accuracy in predicting the success of metaphase CGH.
- the addition of the PCR on the shortest Mse-fragment PHACTR2 slightly increased the assay accuracy in the collective of 72 DCC genomes.
- Alternative 2 QC assay with 4 markers (D5S2117, TRP53-Ex2/3, CK19 and PHACTR2). Table 2. Assay accuracy of two alternative marker combinations for the QC assay (72 DCC samples) Statistical measurement Alternative 1 Alternative 2 2/3 PCRs + 3/3 PCRs + 3/4 PCRs + 4/4 PCRs + True + 35 29 35 29 False - 1 7 1 7 True - 34 36 35 36 False + 2 0 1 0 Sensitivity 0.97 0.81 0.97 0.81 Specificity 0.94 1.0 0.97 1.0 Positive predictive value 0.95 1.0 0.97 1.0 Negative predictive value 0.97 0.84 0.97 0.84
- Step 1 95.0°C 4 min
- Step 2 95.0°C 30 s
- Step 3 58.0°C 30 s
- Step 4 72.0°C 90 s 32 cycles (steps 2-4)
- Step 5 72.0°C 7 min
- Step 6 4.0°C forever
- PCR products may be:
- Figure 3 shows an example of an agarose gel electrophoresis of PCR products obtained from different samples by using the above disclosed 4 multiplex assay.
- Sample 1 in Figure 3 for example displays 3/4 positive markers.
- Marker B heterozygosity or homozigosity one or two bands must be counted as one in the evaluation of the positivity for marker B.
- Samples 2 and 8 for example display 4/4 positive markers.
- the KRAS 91bp amplicon was detected in all 38 samples that showed one or more bands in the currently used 3-multiplex. Additionally, 15 samples were identified that were negative for D5S2117, CK19 and TP53-Exon2/3 but positive for KRAS91bp, only. Finally 18 samples were negative for all four tested amplicons.
- PIK3CA sequence analysis 4 breast DCC samples, 3 prostate DCC samples, and 3 melanoma DCC samples.
- PIK3CA PCRs were performed for HS1 and HS2 fragments, using Ampli1TM PIK3CA Seq Kit (Silicon Biosystems SpA, Italy), according to the manufacturer instructions. After PCR all samples were loaded on a 1.5% agarose gel and amplicons visualized after electrophoresis.
- Genome Integrity was assessed by analysing the quality of Ampli1TM WGA product according to the invention.
- the resulting number of PCR products detected following the multiplex PCR reaction was found to be significantly skewed, as shown in Figure 4 , toward lower values of GII in CTCs with respect to normal WBCs collected from the same patients, undergoing the same process of enrichment sorting and Ampli1TM WGA.
- a GII with a value of 0 corresponds to a situation in which none of the first, second, third or fourth PCR products is amplified
- a GII with a value of 1 corresponds to a situation in which only the fourth PCR product is amplified
- a GII with a value of 2 corresponds to a situation in which one among the first, second and third PCR products and the fourth PCR product are amplified
- a GII with a value of 3 corresponds to a situation in which two among the first, second and third PCR products and the fourth PCR product are amplified
- a GII with a value of 4 corresponds to a situation in which the first, second, third and fourth PCR products are amplified.
- the GII was further used to assess the success rate of targeted Sanger sequencing for PIK3CA exon 9 and exon 20 mutation hotspots, of a custom qPCR assay to determine the amplification of ERBB2 gene, and of array CGH. Table 5 shows a synopsis of the results.
- the method according to the present invention allows to determine the integrity of the genome of a sample and the quality of a library of DNA sequences obtained by DRS-WGA of the genome of the sample with robust and reliable results and allows in particular to predict the performance of molecular assays, such as metaphase and array comparative genomic hybridization (CGH), Sanger sequencing and qPCR, downstream of the DRS-WGA.
- CGH metaphase and array comparative genomic hybridization
- Sanger sequencing and qPCR downstream of the DRS-WGA.
- DRS-WGA is based on specific restriction digestion of double stranded DNA at MseI site (TTAA) and ligation of one universal adaptor for amplification
- TTAA MseI site
- all fragments generated during amplification that represent the WGA library are known.
- first, second and third primer pairs have been specifically selected in target regions of the genome corresponding to long amplicons of the DRS-WGA DNA digestion enzyme, MseI, which are more difficult to amplify in case of DNA fragmentation, their amplification is indicative of good overall success of the DRS-WGA on a given sample.
- the method allows to assess the integrity of the genome of a sample and/or the quality of the library of DNA sequences obtained over the broadest region of the genome.
- first, second, third and fourth PCR products have different size
- the fourth primer pair hybridises to a DNA sequence of the library having a length from 80 bp to 300 bp
- the success rate in e.g. targeted sanger sequencing of the PIK3CA exon 9 (30%) and exon 20 (34%) or qPCR for Her2 CNV analysis (25%) of cells for which not even this fourth PCR product is amplified and those cells for which at least this is amplifiable, for which the success rate roughly doubles (56%, 72%, 50% respectively).
- the two populations would otherwise be indistinguishable when using only the 3 primer pairs hybridizing to long amplicons of the DRS-WGA.
- the method may be multiplexed by using further pairs of primers which do not interfere with the PCR amplification with the first, second, third and possibly fourth primer.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Description
- The present invention relates to a method and a kit for determining the integrity of the genome of a sample, in particular a single cell, and/or the quality of a library of DNA sequences obtained by deterministic restriction site whole genome amplification (DRS-WGA) of the genome of the sample.
- Whole Genome Amplification (WGA) permits detection of somatic mutations and copy alterations in DNA of limited starting material, such as in the case of single circulating tumour cells (CTC) of cancer patients or in preimplantation diagnostics.
- For the diagnostic use of WGA for single cell analysis, quality of genomic DNA (i.e. genome integrity) of the single cell sample of interest plays a major role for successful molecular analysis after WGA.
- In particular, CTCs have been described as being frequently apoptotic (Mehes, G., et al., Circulating breast cancer cells are frequently apoptotic. Am J Pathol, 2001. 159 (1) : p.17-20).
- Moreover, during caspase-mediated apoptosis genomic DNA is fragmented into small pieces of 180 bp to 200 bp length (Wyllie, AH., Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature, 1980. 284(5756): p.555-6).
- It is thus important to assess the Genome Integrity status of a single cell, as this can be linked to the biological status of the cell itself, and give clinically relevant information on the overall status of a cancer patient, which goes beyond the information provided by just counting the CTCs and complements the molecular characterization of those CTCs.
- Besides, DNA crosslinking and/or fragmentation occur with chemical treatment (e.g. fixation) applied on patient-derived cells and tissues for needed sample conservation after biopsy.
- To predict performance of molecular assays for single cell analysis and evaluation of resulting data derived from such samples, assessing the genomic integrity of single cells is of paramount importance.
- Available single cell WGA kits assess quality of whole genome amplification by measuring the concentration of the WGA product only. As protocols for these methods include at least one random step during the procedure of single cell DNA amplification, specific assays to evaluate genome integrity of the input sample (in general a single cell) such as apoptotic or non-apoptotic status, or the quality of the output of the WGA product, such as the suitability for further genetic analysis, are difficult.
- A specific kind of WGA is deterministic restriction site whole genome amplification (hereinafter referred to as DRS-WGA). DRS-WGA, which is known from
EP1109938 and is commercialised as Ampli1™ by Silicon Biosystems Spa, is based on specific restriction digestion of double stranded DNA at MseI sites (TTAA) and ligation of a universal adaptor for amplification. - DRS-WGA has been shown to be better for the amplification of single cells (see for example: Lee YS, et al: Comparison of whole genome amplification methods for further quantitative analysis with microarray-based comparative genomic hybridization. Taiwan J Obstet Gynecol. 2008, 47(1):32-41) and also more tolerant to DNA degradation due to fixative treatment (see for example: Stoecklein N.H. et al: SCOMP is Superior to Degenerated Oligonucleotide Primed-PCR for Global Amplification of Minute Amounts of DNA from Microdissected Archival Samples. American Journal of Pathology 2002, Vol. 161, No. 1; Arneson N. et al.: Comparison of Whole Genome Amplification methods for analysis of DNA extracted from microdissected early breast lesions in formalin-fixed paraffin-embedded tissue. ISRN Oncol. 2012; 2012;710692).
- To date there are no specific assays to evaluate the genome integrity of an input sample from the DRS-WGA product or the quality of the DRS-WGA product obtained.
- A need is therefore felt to develop methods and kits allowing to determine the genome integrity of an input sample and/or the quality of the DRS-WGA product obtained and permitting to predict performance of molecular assays downstream of DRS-WGA for single cell analysis and evaluation of resulting data.
- An object of the present invention is therefore to provide a method for determining the integrity of the genome of a sample and/or the quality of a library of DNA sequences obtained by DRS-WGA that provides robust and reliable results and allows in particular to predict the performance of molecular assays downstream of the DRS-WGA.
- This object is achieved by the present invention as it relates to a method as defined in
claim 1. - It is a further object of the present invention to provide a kit as defined in
claim 8. - Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
- By the term "sample", there is intended a sample comprising at least one particle of a biological entity, said particle comprising at least a DNA sequence representing the genome or a substantial subset of the genome of that biological entity. Said entity is a human, said at least one particle may be a single cell, or a single-cell nucleus, or a haploid germ cell, or a chromosome.
- By the term "genome" there is intended the entire genome or said substantial subset of the genome.
- By the term "integrity" of the genome there is intended the absence of DNA damages such as double strand breaks, or nicks or similar conditions which may hamper the replication of the genome or its normal functionality.
- By the term "quality" of a library of DNA sequences there is intended the suitability of the library of DNA sequences to be used for the genetic characterization of certain features such as, by way of non-limiting example, the presence of point mutations, deletions, insertions, copy number variations.
-
-
Figure 1 shows an agarose gel picture of single marker PCRs, and of a 4-multiplex assay and a 3-multiplex assay according to preferred embodiments of the present invention; -
Figure 2 shows an agarose gel picture of PCRs onPIK3CA hotspot 1 and hotspot2 (M=size marker, 01 = breast13, 02 = breast15, 03 = breast17, 04 = breast20, 05 = prostate14, 06 = prostate16, 07 = prostate24, 08= melanoma13, 09 = melanoma14, 10 = melanoma16); -
Figure 3 shows an agarose gel picture of 8 samples tested by the preferred 4-multiplex assay ofFigure 1 . -
Figure 4 shows a histogram of the distribution of the Genome Integrity Index among single Circulating Tumour Cells (CTCs) and single leukocytes (WBCs) from breast cancer patients. - The method according to the present invention for determining the integrity of the genome of a sample and/or the quality of a library of DNA sequences obtained by deterministic restriction site whole genome amplification (DRS-WGA) of the genome of the sample comprises steps (a) to (d) of
claim 1. By allowing the determination of the integrity of the genome of a sample and/or the quality of a library of sequences obtained by DRS-WGA of the genome of the sample, the method also allows to predict the success rate of genetic analysis assays on the library of DNA sequences. - The sample may preferably be a circulating tumour cell (CTC), a circulating fetal cell, a circulating endothelial cell (CEC), an oocyte, a cumulus cell, a sperm, a blastomere, or a trophectoderm cell.
- In step (a), the library of DNA sequences is provided.
- In step (b), the library of DNA sequences is amplified by PCR using at least one first primer pair which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp, preferably from 1000 bp to 2000 bp, and corresponding to a sequence of the genome located on a first chromosome arm, the step of amplifying giving rise to a first PCR product from 50 bp to 1000 bp.
- Preferably, the DNA sequence of the library to which the first primer pair hybridises encompasses the D5S2117 region of chromosome 5q.
- More preferably, the forward primer of the first primer pair is SEQ ID NO:4 and the reverse primer of the first primer pair is SEQ ID NO:3.
- In step (c) the first PCR product is detected. Agarose gel electrophoresis may be used to separate and detect the PCR product as well as other methods known in the art.
- In step (d) the presence of the first PCR product is correlated with the integrity of the genome of the sample and/or the quality of the library of DNA sequences. In step (b) at least one second primer pair is used which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp, more preferably from 1000 bp to 2000 bp, and corresponding to a sequence of the genome located on a second chromosome arm other than the first chromosome arm, the step of amplifying giving rise to a second PCR product from 50 bp to 1000 bp having a size other than the first PCR product.Step (b) uses at least one second primer pair, the second PCR product is also detected in step (c) and the presence of the second PCR product is also correlated with the integrity of the genome of the sample and/or the quality of the library of DNA sequences in step (d).
- Preferably, the DNA sequence of the library to which the second primer pair hybridises encompasses
exons - More preferably, the forward primer of the second primer pair is SEQ ID NO:6 and the reverse primer of second primer pair is SEQ ID NO:5.In step (b) at least one third primer pair is used which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp, more preferably from 1000 bp to 2000 bp, and corresponding to a sequence of the genome located on a third chromosome arm other than the first and second chromosome arms, the step of amplifying giving rise to a third PCR product from 50 bp to 1000 bp having a size other than the first and second PCR products. Step (b) uses at least one third primer pair, the third PCR product is also detected in step (c) and the presence of the third PCR product is also correlated with the integrity of the genome of the sample and/or the quality of the library of DNA sequences in step (d).The DNA sequence of the library to which the third primer pair hybridises encompasses the KRT19 pseudo-gene 1 (indicated for short as CK19).
- More preferably, the forward primer of the third primer pair is SEQ ID NO:8 and the reverse primer of the third primer pair is SEQ ID NO:7.
- Even more preferably, in step (b) at least one fourth primer pair is used which hybridises to a DNA sequence of the library having a length from 80 bp to 300 bp, the step of amplifying giving rise to a fourth PCR product from 50 bp to 200 bp having a size other than the first, the second and the third PCR products.
- When step (b) uses at least one fourth primer pair, the fourth PCR product is also detected in step (c) and the presence of the fourth PCR product is also correlated with the integrity of the genome of the sample and/or the quality of the library of DNA sequences in step (d).
- Preferably, the DNA sequence of the library to which the fourth primer pair hybridises encompasses codons 12 and 13 of the KRAS gene.
- Even more preferably, the forward primer of the fourth primer pair is SEQ ID NO:17 and the reverse primer of the fourth primer pair is SEQ ID NO:18.
- According to the present invention there is also provided a kit for determining the integrity of the genome of a sample and/or the quality of a library of DNA sequences obtained by deterministic restriction site whole genome amplification (DRS-WGA) of the genome of the sample comprising at least one of:
- at least one first primer pair which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp and corresponding to a sequence of the genome located on a first chromosome arm,
- at least one second primer pair which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp and corresponding to a sequence of the genome located on a second chromosome arm other than the first chromosome arm,
- at least one third primer pair which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp and corresponding to a sequence of the genome located on a third chromosome arm other than the first and second chromosome arms, wherein the first, second and third primer pairs give rise, when amplified by PCR, to PCR products having different size from one another.
- Preferably the kit comprises the first, second and third primer pairs.
- Preferably, the kit further comprises at least one fourth primer pair which hybridises to a DNA sequence of the library having a length from 80 bp to 300 bp, wherein the first, second, third and fourth primer pairs give rise, when amplified by PCR, to PCR products having different size from one another.
- More preferably, the kit comprises the first, second, third and fourth primer pairs.
- The kit may be used for predicting the success of a genetic analysis assay after amplification of single cell genomic DNA by DRS-WGA. Preferably the genetic analysis assay is Sanger sequencing for mutation analysis, assessment of specific copy number changes, quantitative PCR for gene amplification, metaphase Comparative Genomic Hybridisation (CGH), or array Comparative Genomic Hybridisation (CGH).
- For gene specific assays, such as Sanger sequencing for mutation analysis, samples with at least 1-2 out of 4 PCR products can be used. Positivity to at least 3 out of 4 PCR products is predictive of successful genome-wide analysis with metaphase CGH. For array CGH it is advisable to use samples with 4 out of 4 positive PCR products.
- In brief, several primer pairs designed on MseI fragments located on different chromosomal locations and with varying fragment lengths were tested. Three primer pairs that predict successful whole genome analysis of single cell products with high specificity and sensitivity were selected (Example 1). A fourth primer pair of a shorter MseI fragment was added to indicate successful DRS-WGA of low quality cells, e.g. apoptotic CTCs (Example 2). In the examples, PCR products are also referred to as "markers" and PCR amplification reactions including several primer pairs are also referred to as "multiplex assays". In particular, PCR amplification reactions including several primer pairs designed to determine the integrity of the genome of a sample and/or the quality of the library of DNA sequences obtained by deterministic restriction site whole genome amplification (DRS-WGA) of the genome of the sample are also referred to as "quality control assays" or "QC assays".
- Two alternative marker combinations were shown to predict the success of metaphase comparative genomic hybridization (CGH) after amplification of single cell genomic DNA with DRS-WGA (Resolution 10-20 Mb) on both cancer cell samples and samples of diploid cells with normal karyotype.
- PCRs on 8 different MseI-fragments covering an MseI-fragment length from 239-1936 bp were tested (Table 1). Sequences located on 7 different chromosome arms were selected to minimize the chance of a negative assay result because of genomic DNA loss in a single cancer cell.
Pipetting scheme (1x) 1.0 µl Buffer +dNTPs (10mM MgCl, 100mM Tris (pH 8.5), 500 mM KCl, 1mM dNTPs) 0.5 µl Primer 3' (8 µM) 0.5 µl Primer 5' (8 µM) 0.25 µl BSA (for molecular biology) 7.25 µl PCR-H2O 0.1 µl Taq polymerase (5U/µl) 0.5 µl Ampli1 product (test sample) -
Step 194.0° C 2 min Step 2 Annealing Temp 30 s Step 372.0° C 2 min Step 4 94.0°C 15 s Step 5Annealing Temp 30 s Step 672.0°C 20 s 14 additional cycles (steps 4-6) Step 794.0°C 15 s Step 8Annealing Temp 30 s Step 9 72.0°C 30 s 24 additional cycles (steps 7-9) Step 1072.0° C 2 min Step 11 4°C forever Table 1. Features of the 8 selected PCR primer pairs tested for the QC assay to assess DRS-WGA quality Primer name SEQ ID NO Sequence Annealing temperature Chromosome Mse-fragment length PCR-fragment length BCR-TT-R 1 TCAGCCTCAGGACTCTTGTG 61°C 22q 1936 bp 323 bp BCR-TT-F 2 CGTGGACAACTACGGAGTTG 61°C 22q 1936 bp 323 bp D5S2117-R 3 ACTGAGTCCTCCAACCATGG 58°C 5q 1376 bp 140 bp* D5S2117-F 4 CCAGGTGAGAACCTAGTCAG 58°C 5q 1376 bp 140 bp* TRP53-Ex2/3-R 5 CAGCCCAACCCTTGTCCTTA 58°C 17p 1374 bp 299 bp TRP53-Ex2/3-F 6 GAAGCGTCTCATGCTGGATC 58°C 17p 1374 bp 299 bp CK19-R 7 TTCATGCTCAGCTGTGACTG 58°C 6q 1146 bp 614 bp CK19-F 8 GAAGATCCGCGACTGGTAC 58°C 6q 1146 bp 614 bp IGF2R-R 9 GGATCTTGGTACCACTCATG 58°C 6q 647 bp 217 bp IGF2R-F 10 GCCACTGTCGAAGTCTGCA 58°C 6q 647 bp 217 bp RUFY2-R 11 64°C 10q 458 bp 104 bp RUFY2-F 12 64°C 10q 458 bp 104 bp SMYD1-R 13 CTTTTCCCTGAAGGTCTTAG 55°C 2p 287 bp 163 bp SMYD1-F 14 GGGTGACCTGCTTGACATC 55°C 2p 287 bp 163 bp PHACTR2-R 15 TGTGAGAAAGACTTGGAGTT 58°C 6q 239 bp 205 bp PHACTR2-F 16 ACTGAACAGAGCAGGTCTAC 58°C 6q 239 bp 205 bp * This primer pair amplifies a microsatellite sequence. Therefore the actual fragment length can vary slightly between alleles of one patient and between different patients. - To select the best possible combination of PCR markers, 72 single cell genomes from different types of human cancers (24 breast disseminated cancer cells (DCCs) 24 prostate DCCs, 24 melanoma DCCs) were re-amplified. For each of the three groups, 12 cells were included which resulted in successful metaphase hybridization in a previous CGH experiment and 12 cells which resulted in a failed metaphase hybridization in a previous CGH experiment. Specific PCRs for all selected markers were performed and the assay was evaluated for accuracy in predicting the outcome of metaphase CGH.
- As single markers, PCRs on the long Mse-fragments D5S2117, TRP53-Ex2/3 and KRT19 pseudogene 1 (hereinafter also referred to as CK19) provided best separation between amplified genomes with successful and failed metaphase CGH. An assay of these three fragments showed high assay accuracy in predicting the success of metaphase CGH. The addition of the PCR on the shortest Mse-fragment PHACTR2 slightly increased the assay accuracy in the collective of 72 DCC genomes.
- In summary, two alternative QC assays for the QC kit for Ampli1 were developed (Table 2).
- Alternative 1: QC assay with 3 markers (D5S2117, TRP53-Ex2/3 and CK19).
- Alternative 2: QC assay with 4 markers (D5S2117, TRP53-Ex2/3, CK19 and PHACTR2).
Table 2. Assay accuracy of two alternative marker combinations for the QC assay (72 DCC samples) Statistical measurement Alternative 1 Alternative 22/3 PCRs + 3/3 PCRs + 3/4 PCRs + 4/4 PCRs + True + 35 29 35 29 False - 1 7 1 7 True - 34 36 35 36 False + 2 0 1 0 Sensitivity 0.97 0.81 0.97 0.81 Specificity 0.94 1.0 0.97 1.0 Positive predictive value 0.95 1.0 0.97 1.0 Negative predictive value 0.97 0.84 0.97 0.84 - If possible, only samples that are of the highest quality and that are positive for all selected markers (for both alternative assays 100% specificity) should be used. However, the trade-off for applying this high standard of quality control is a high rate of false negatives (7/36 = 19.4%). If the number of test samples with the highest quality standard is limited, DRS-WGA amplified genomes with 2/3 or 3/4 positive PCRs still predict a high success rate for metaphase CGH (specificity 0.94 for assay with 3 markers and 0.97 for assay with 4 markers, respectively).
- To further test the set of PCR markers for the QC assay, 100 single cell genomes from diploid cells with normal karyotypes were re-amplified. All samples were tested for the 8 different PCR markers. Additionally, metaphase CGH success was checked for 22 genomes with predicted good quality and 10 genomes with predicted bad quality. The results of the statistical evaluation of assay accuracy are shown in Table 3.
Table 3. Assay accuracy of two alternative marker combinations for the Ampli1 QC kit (32 normal samples) Statistical measurement Alternative 1 Alternative 22/3 PCRs + 3/3 PCRs + 3/4 PCRs + 4/4 PCRs + True + 22 21 22 21 False - 0 1 0 1 True - 10 10 10 10 False + 0 0 0 0 Sensitivity 1.0 0.95 1.0 0.95 Specificity 1.0 1.0 1.0 1.0 Positive predictive value 1.0 1.0 1.0 1.0 Negative predictive value 1.0 0.91 1.0 0.91 - As the tested samples in B and C were taken from an existing biobank of single cell genomes, they were amplified with DRS-WGA customized reagents of the related labs (provided by different suppliers). To validate the performance of the proposed QC assay with samples amplified by Ampli1 kit (as provided by Silicon Biosystems), single mononuclear PBLs and cell pools of a healthy donor and single cells and cell pools of the breast cancer cell line SKBR3 were isolated. The markers proposed in B and C for the QC assay were used to predict quality of the amplified genomes. Then, metaphase CGH experiments for a set of samples (5 single cells, 1 cell pool and 1 Ampli1 negative control) for diploid blood cells as well as SKBR3 cells were performed to validate the predictive accuracy of the QC assay.
SKBR: 10/11 single cells and both cell pools showed 4/4 positive bands marker PCRs 1/11 cells was negative for all tested markers negative control clean in all tested PCRs PBL: 11/11 single cells and both cell pools showed 4/4 positive bands marker PCRs negative control clean in all tested PCRs - As other downstream analyses, e.g. Sanger sequencing for specific fragments, are not dependent on a quantitatively and qualitatively very high amplification of the single cell DNA, a fourth fragment was included. Experiments were carried out to test whether a successful amplification of this sequence only is enough to predict success of Sanger sequencing of comparable Mse fragments (here PIK3CA
hotspots 1 and 2). - In order to have compatibility with the already established 3-multiplex assay, new primers were designed for the KRAS Mse-fragment encompassing the frequently mutated nucleotides encoding for codons 12 and 13. These primers amplify a PCR fragment of 91 bp length clearly distinguishable from the other three bands (D5S2117, CK19 and TP53-Exon2/3, see
Figure 1 ). - The following pipetting scheme and thermal profile were used adding the following KRAS primers in a concentration of 4 µM to the primer mix.
- KRAS91bp-F ATAAGGCCTGCTGAAAATGAC (SEQ ID NO:17)
- KRAS91bp-R CTGAATTAGCTGTATCGTCAAGG (SEQ ID NO:18)
-
Step 195.0° C 4 min Step 2 95.0°C 30 s Step 358.0°C 30 s Step 472.0°C 90 s 32 cycles (steps 2-4) Step 572.0° C 7 min Step 6 4.0°C forever - 5 µl of each PCR product were loaded on a 1.2% agarose gel. The results were checked by comparing the obtained amplicons bp length with the expected ones, as shown in table 4.
Table 4 PCR product identification Target Primer marker Chromosome Amplicon length (bp) A KRAS 12p 91 B D5S2117 5q 108-166 C TRP53 17p 299 D KRT19 pseudo-gene 1 (CK19) 6q 614 - As already noted above, marker B maps on a polymorphic region, therefore the PCR products may be:
- homozygous, and show one band of a bp comprised in the described range (108-166);
- heterozygous and show two bands of different bp comprised in the described range (108-166).
-
Figure 3 shows an example of an agarose gel electrophoresis of PCR products obtained from different samples by using the above disclosed 4 multiplex assay. -
Sample 1 inFigure 3 forexample displays 3/4 positive markers. Marker B heterozygosity or homozigosity (one or two bands) must be counted as one in the evaluation of the positivity formarker B. Samples example display 4/4 positive markers. - 72 DRS-WGA libraries of breast, prostate and melanoma DCC that had already been tested by the 3-multiplex assay of Example 1 were selected. Unfortunately the
sample Breast 01 was lost due to a fissure in the reaction tube. All other 71 DRS-WGA products were additionally tested with KRAS 91bp single PCR and the new 4-multiplex assay. In summary, 53/71 samples showed the expected band at 91bp in single marker PCR, and all of them but one (Breast 24) showed the same band in the 4-multiplex assay. All the other bands for D5S2117, CK19 and TP53-Exon2/3 were detected in the same samples than with 3-multiplex assay. Moreover, the KRAS 91bp amplicon was detected in all 38 samples that showed one or more bands in the currently used 3-multiplex. Additionally, 15 samples were identified that were negative for D5S2117, CK19 and TP53-Exon2/3 but positive for KRAS91bp, only. Finally 18 samples were negative for all four tested amplicons. - Out of the 15 samples which showed the KRAS 91bp amplicon only, ten samples were selected for PIK3CA sequence analysis (4 breast DCC samples, 3 prostate DCC samples, and 3 melanoma DCC samples). PIK3CA PCRs were performed for HS1 and HS2 fragments, using Ampli1™ PIK3CA Seq Kit (Silicon Biosystems SpA, Italy), according to the manufacturer instructions. After PCR all samples were loaded on a 1.5% agarose gel and amplicons visualized after electrophoresis. Strong bands were obtained only for HS1 in four DCC samples (prostate DCC 16, melanoma DCCs 13, 14, and 16) and for HS2 in five DCC samples (prostate DCCs 14, and 16, melanoma DCCs 13, 14, and 16). Additionally, weak but visible bands were detected for an additional two (breast DCC 13, prostate DCC 24) and three samples (
breast DCCs 13, and 15, prostate DCC 24), respectively (Figure 2 ). One sample (melanoma DCC 16) showed a strong smear for DNA fragment ≥ 1kb, which was also visible in all previous gels of this sample. Nevertheless, the PCR amplicon was purified for all samples and sequenced. - Sanger sequencing for PIK3CA mutational hotspots resulted in very strong and clean sequences for the samples showing strong amplification in gel electrophoresis (see
Figure 2 ), including sample melanoma DCC 16. Most of the other samples with lower amplicon concentration showed high background noise, although sequences could easily be edited for two additional samples for HS1 (breast DCC 13, prostate DCC 24) and four additional samples for HS2 (breast DCCs breast DCCs breast DCC 15 for HS2). - On a collective of CTCs and White Blood Cells (WBCs) harvested with DEPArray™ (Silicon Biosystems SpA) from breast cancer patients peripheral blood enriched with CellSearch® (Jannsen Diagnostics LLC), the Genome Integrity was assessed by analysing the quality of Ampli1™ WGA product according to the invention. The resulting number of PCR products detected following the multiplex PCR reaction (Genome Integrity Index or GII) was found to be significantly skewed, as shown in
Figure 4 , toward lower values of GII in CTCs with respect to normal WBCs collected from the same patients, undergoing the same process of enrichment sorting and Ampli1™ WGA. - By way of explanation, a GII with a value of 0 corresponds to a situation in which none of the first, second, third or fourth PCR products is amplified, a GII with a value of 1 corresponds to a situation in which only the fourth PCR product is amplified, a GII with a value of 2 corresponds to a situation in which one among the first, second and third PCR products and the fourth PCR product are amplified, a GII with a value of 3 corresponds to a situation in which two among the first, second and third PCR products and the fourth PCR product are amplified, and a GII with a value of 4 corresponds to a situation in which the first, second, third and fourth PCR products are amplified.
- The GII was further used to assess the success rate of targeted Sanger sequencing for PIK3CA exon 9 and
exon 20 mutation hotspots, of a custom qPCR assay to determine the amplification of ERBB2 gene, and of array CGH. Table 5 shows a synopsis of the results.Table 5 Molecular assay Analyzed cells Genome Integrity Index (GII) P Value GII 0 GII 1GII 2GII 3GII 4Chi-square PIK3CA HS1 n=383 7/23 (30.4%) 14/25 (56.0%) 48/62 (77.4%) 102/117 (87.2%) 146/156 (93.6%) <0.0001 PIK3CA HS2 n=383 8/23 (34.8%) 18/25 (72.0%) 55/62 (88.7%) 109/117 (93.2%) 149/156 (95.5%) <0.0001 PIK3CA complete n=383 4/23 (17.4%) 12/25 (48.0%) 45/62 (72.6%) 97/117 (82.9%) 141/156 (90.4%) <0.0001 HER2 qPCR n=351 3/12 (25.0%) 8/18 (50.0%) 41/61 (67.2%) 95/112 (84.8%) 136/148 (91.9%) <0.0001 aCGH n=50 Not assessed Not assessed 4/5 (80.0%) 7/9 (77.8%) 36/36 (100%) 0.016 - The above examples show that the method according to the present invention allows to determine the integrity of the genome of a sample and the quality of a library of DNA sequences obtained by DRS-WGA of the genome of the sample with robust and reliable results and allows in particular to predict the performance of molecular assays, such as metaphase and array comparative genomic hybridization (CGH), Sanger sequencing and qPCR, downstream of the DRS-WGA.
- From an analysis of the features of the method and kit of the present invention, the resulting advantages are apparent.
- In particular, in virtue of the fact that DRS-WGA is based on specific restriction digestion of double stranded DNA at MseI site (TTAA) and ligation of one universal adaptor for amplification, in principle all fragments generated during amplification that represent the WGA library are known. Thus, by the identification of specific MseI fragments having a length of > 1000 bp in a single cell WGA library, the genomic integrity of the DNA of an isolated cell can be measured, and thus the quality of the sample for different kinds of successful molecular analysis determined.
- Since the first, second and third primer pairs have been specifically selected in target regions of the genome corresponding to long amplicons of the DRS-WGA DNA digestion enzyme, MseI, which are more difficult to amplify in case of DNA fragmentation, their amplification is indicative of good overall success of the DRS-WGA on a given sample.
- Further, in virtue of the fact that the first, second and third primer pairs are designed on different chromosome arms, the method allows to assess the integrity of the genome of a sample and/or the quality of the library of DNA sequences obtained over the broadest region of the genome.
- Further, in virtue of the fact that the first, second, third and fourth PCR products have different size, it is possible to use the first, second, third and fourth primer pairs together in a multiplex reaction.
- Moreover, in virtue of the fact that the fourth primer pair hybridises to a DNA sequence of the library having a length from 80 bp to 300 bp, it is possible to predict the performance of molecular assays downstream of the DRS-WGA also for low quality cells, for example apoptotic CTCs. In fact there is a significant difference in performance between the success rate in e.g. targeted sanger sequencing of the PIK3CA exon 9 (30%) and exon 20 (34%) or qPCR for Her2 CNV analysis (25%) of cells for which not even this fourth PCR product is amplified and those cells for which at least this is amplifiable, for which the success rate roughly doubles (56%, 72%, 50% respectively). The two populations would otherwise be indistinguishable when using only the 3 primer pairs hybridizing to long amplicons of the DRS-WGA.
- Finally, it is clear that modifications and variants to the method and kit disclosed and shown may be made without departing from the scope of protection of the appended claims.
- In particular, the method may be multiplexed by using further pairs of primers which do not interfere with the PCR amplification with the first, second, third and possibly fourth primer.
-
- <110> Silicon Biosystems s.p.A. and Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
- <120> METHOD AND KIT FOR DETERMINING THE GENOME INTEGRITY AND/OR THE QUALITY OF A LIBRARY OF DNA SEQUENCES OBTAINED BY DETERMINISTIC RESTRICTION SITE WHOLE GENOME AMPLIFICATION
- <160> 18
- <170> BiSSAP 1.0
- <210> 1
<211> 20
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..20
<223> /mol_type="DNA" /note="BCR-TT-3'" /organism="Homo sapiens" - <400> 1
tcagcctcag gactcttgtg 20 - <210> 2
<211> 20
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..20
<223> /mol_type="DNA" /note="BCR-TT-5'" /organism="Homo sapiens" - <400> 2
cgtggacaac tacggagttg 20 - <210> 3
<211> 20
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..20
<223> /mol_type="DNA" /note="D5s2117-3'" /organism="Homo sapiens" - <400> 3
actgagtcct ccaaccatgg 20 - <210> 4
<211> 20
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..20
<223> /mol_type="DNA" /note="D5s2117-5'" /organism="Homo sapiens" - <400> 4
ccaggtgaga acctagtcag 20 - <210> 5
<211> 20
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..20
<223> /mol_type="DNA" /note="TRP53-Ex2/3-3"' /organism="Homo sapiens" - <400> 5
cagcccaacc cttgtcctta 20 - <210> 6
<211> 20
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..20
<223> /mol_type="DNA" /note="TRP53-Ex2/3-5'" /organism="Homo sapiens" - <400> 6
gaagcgtctc atgctggatc 20 - <210> 7
<211> 20
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..20
<223> /mol_type="DNA" /note="CK12-3'" /organism="Homo sapiens" - <400> 7
ttcatgctca gctgtgactg 20 - <210> 8
<211> 19
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..19
<223> /mol_type="DNA" /note="CK12-5'" /organism="Homo sapiens" - <400> 8
gaagatccgc gactggtac 19 - <210> 9
<211> 20
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..20
<223> /mol_type="DNA" /note="IGF2R-3'" /organism="Homo sapiens" - <400> 9
ggatcttggt accactcatg 20 - <210> 10
<211> 19
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..19
<223> /mol_type="DNA" /note="IGF2R-59" /organism="Homo sapiens" - <400> 10
gccactgtcg aagtctgca 19 - <210> 11
<211> 22
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..22
<223> /mol_type="DNA" /note="RUFY2-3'" /organism="Homo sapiens" - <400> 11
cagctaggaa ctccaggaat ca 22 - <210> 12
<211> 23
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..23
<223> /mol_type="DNA" /note="RUFY2-5'" /organism="Homo sapiens" - <400> 12
gttgagggct tcatcaacac cca 23 - <210> 13
<211> 20
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..20
<223> /mol_type="DNA" /note="SMYD1-3'" /organism="Homo sapiens" - <400> 13
cttttccctg aaggtcttag 20 - <210> 14
<211> 19
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..19
<223> /mol_type="DNA" /note="SMYD1-5'" /organism="Homo sapiens" - <400> 14
gggtgacctg cttgacatc 19 - <210> 15
<211> 20
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..20
<223> /mol_type="DNA" /note="PHACTR2-3'" /organism="Homo sapiens" - <400> 15
tgtgagaaag acttggagtt 20 - <210> 16
<211> 20
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..20
<223> /mol_type="DNA" /note="PHACTR2-5'" /organism="Homo sapiens" - <400> 16
actgaacaga gcaggtctac 20 - <210> 17
<211> 21
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..21
<223> /mol_type="DNA" /note="KRAS 91bp 5' " /organism="Homo sapiens" - <400> 17
ataaggcctg ctgaaaatga c 21 - <210> 18
<211> 23
<212> DNA
<213> Homo sapiens - <220>
<221> source
<222> 1..23
<223> /mol_type="DNA" /note="KRAS 91bp 3' " /organism="Homo sapiens" - <400> 18
ctgaattagc tgtatcgtca agg 23
Pipetting scheme (1x) | 1.0 µl | Ampli1™ PCR Reaction Buffer (20mM MgCl2 included) |
0.2 µl | dNTPs (10mM) | |
1.0 µl | Primer mix (8 primers, each 4 µM) | |
0.2 µl | BSA (20 mg/ml) | |
6.5 µl | PCR-H2O | |
0.1 µl | Ampli1™ Taq polymerase (5U/µl) | |
1.0 µl | Ampli1™ product (test sample) |
Claims (11)
- A method for determining the integrity of the human genome of a sample to be analysed by whole genome amplification (WGA) and/or the quality of a library of DNA sequences obtained by deterministic restriction site whole genome amplification (DRS-WGA) of the human genome of the sample comprising the steps of:(a) providing the library of DNA sequences,(b) amplifying the library of DNA sequences by PCR using:- at least one first primer pair which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp and encompassing the D5S2117 region of chromosome 5q of the genome,- at least one second primer pair which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp and encompassing exons 2 and 3 of the TRP53 gene of the genome, and- at least one third primer pair which hybridises to a DNA sequence of the library having a length from 1000 bp to 5000 bp and encompassing the KRT19 pseudo-gene 1 of the genome,the step of amplifying giving rise to a first PCR product from 50 bp to 1000 bp, a second PCR product from 50 bp to 1000 bp having a size other than the first PCR product, and a third PCR product from 50 bp to 1000 bp having a size other than the first and second PCR products;(c) detecting the first, second and third PCR products;(d) correlating the presence of the first, second and third PCR products with the integrity of the genome of the sample and/or the quality of the library of DNA sequences.
- The method according to claim 1, wherein the forward primer of the at least one first primer pair is SEQ ID NO:4 and the reverse primer of the at least one first primer pair is SEQ ID NO:3.
- The method according to claim 1 or 2, wherein the forward primer of the at least one second primer pair is SEQ ID NO:6 and the reverse primer of the at least one second primer pair is SEQ ID NO:5.
- The method according to any of claims 1 to 3, wherein the forward primer of the at least one third primer pair is SEQ ID NO:8 and the reverse primer of the at least one third primer pair is SEQ ID NO:7.
- The method according to any of claims 2 to 4, wherein step (b) further uses at least one fourth primer pair which hybridises to a DNA sequence of the library having a length from 80 bp to 300 bp, the step of amplifying giving rise to a fourth PCR product from 50 bp to 200 bp having a size other than the first, the second and the third PCR products;- step (c) further comprises detecting the fourth PCR product;- step (d) further comprises correlating the presence of the fourth PCR product with the integrity of the genome of the sample and/or the quality of the library of DNA sequences.
- The method according to claim 5, wherein the DNA sequence of the library to which the at least one fourth primer pair hybridises encompasses Codon 12/13 of the KRAS gene.
- The method according to claim 6, wherein the forward primer of the at least one fourth primer pair is SEQ ID NO: 17 and the reverse primer of the at least one fourth primer pair is SEQ ID NO:18.
- A kit for implementing the method according to any of claims 1 to 7 comprising:- at least one first primer pair which hybridises to a DNA sequence of the human library having a length from 1000 bp to 5000 bp and encompassing the D5S2117 region of chromosome 5q of the genome,- at least one second primer pair which hybridises to a DNA sequence of the human library having a length from 1000 bp to 5000 bp and encompassing exons 2 and 3 of the TRP53 gene of the genome, and- at least one third primer pair which hybridises to a DNA sequence of the human library having a length from 1000 bp to 5000 bp and encompassing the KRT19 pseudo-gene 1 of the genome,wherein the first, second and third primer pairs give rise, when amplified by PCR, to PCR products having different size from one another.
- The kit according to claim 8, further comprising at least one fourth primer pair which hybridises to a DNA sequence of the library having a length from 80 bp to 300 bp,
wherein the first, second, third and fourth primer pairs give rise, when amplified by PCR, to PCR products having different size from one another. - Use of a kit comprising:- at least one first primer pair which hybridises to a DNA sequence of the human library having a length from 1000 bp to 5000 bp and encompassing the D5S2117 region of chromosome 5q of the genome,- at least one second primer pair which hybridises to a DNA sequence of the human library having a length from 1000 bp to 5000 bp and encompassing exons 2 and 3 of the TRP53 gene of the genome, and- at least one third primer pair which hybridises to a DNA sequence of the human library having a length from 1000 bp to 5000 bp and encompassing the KRT19 pseudo-gene 1 of the genome,wherein the first, second and third primer pairs give rise, when amplified by PCR, to PCR products having different size from one another,
in predicting the success of a genetic analysis assay after amplification of single cell genomic DNA by DRS-WGA. - Use according to claim 10, wherein the genetic analysis assay is selected from the group consisting of Sanger sequencing for mutation analysis, assessment of specific copy number changes, quantitative PCR for gene amplification, metaphase Comparative Genomic Hybridisation (CGH), and array Comparative Genomic Hybridisation (CGH).
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES13195770.6T ES2637385T3 (en) | 2013-12-04 | 2013-12-04 | Method and kit to determine genome integrity and / or the quality of a library of DNA sequences obtained by complete genome amplification by deterministic restriction sites |
PT131957706T PT2881739T (en) | 2013-12-04 | 2013-12-04 | Method and kit for determining the genome integrity and/or the quality of a library of dna sequences obtained by deterministic restriction site whole genome amplification |
DK13195770.6T DK2881739T3 (en) | 2013-12-04 | 2013-12-04 | Method and kit for determining the genome integrity and / or quality of a library of DNA sequences obtained by deterministic restriction site whole-genome amplification |
EP13195770.6A EP2881739B1 (en) | 2013-12-04 | 2013-12-04 | Method and kit for determining the genome integrity and/or the quality of a library of dna sequences obtained by deterministic restriction site whole genome amplification |
CN201480074845.3A CN106030307B (en) | 2013-12-04 | 2014-12-04 | For determining the method and kit of the Library Quality of genomic integrity and/or the DNA sequence dna for passing through the acquisition of certainty restriction site whole genome amplification |
US15/101,299 US10392657B2 (en) | 2013-12-04 | 2014-12-04 | Method and kit for determining the genome integrity and/or the quality of a library of DNA sequences obtained by deterministic restriction site whole genome amplification |
KR1020167017659A KR102275752B1 (en) | 2013-12-04 | 2014-12-04 | Method and kit for determining the genome integrity and/or the quality of a library of dna sequences obtained by deterministic restriction site whole genome amplification |
JP2016536851A JP6543253B2 (en) | 2013-12-04 | 2014-12-04 | Methods and kits for determining the quality of a library of DNA sequences obtained by genomic integrity and / or deterministic restriction enzyme site whole genome amplification |
PCT/IB2014/066602 WO2015083121A1 (en) | 2013-12-04 | 2014-12-04 | Method and kit for determining the genome integrity and/or the quality of a library of dna sequences obtained by deterministic restriction site whole genome amplification |
CA2932524A CA2932524C (en) | 2013-12-04 | 2014-12-04 | Method and kit for determining the genome integrity and/or the quality of a library of dna sequences obtained by deterministic restriction site whole genome amplification |
US16/455,470 US20190316194A1 (en) | 2013-12-04 | 2019-06-27 | Method and kit for determining the genome integrity and/or the quality of a library of dna sequences obtained by deterministic restriction site whole genome amplification |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13195770.6A EP2881739B1 (en) | 2013-12-04 | 2013-12-04 | Method and kit for determining the genome integrity and/or the quality of a library of dna sequences obtained by deterministic restriction site whole genome amplification |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2881739A1 EP2881739A1 (en) | 2015-06-10 |
EP2881739B1 true EP2881739B1 (en) | 2017-05-17 |
Family
ID=49680939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13195770.6A Active EP2881739B1 (en) | 2013-12-04 | 2013-12-04 | Method and kit for determining the genome integrity and/or the quality of a library of dna sequences obtained by deterministic restriction site whole genome amplification |
Country Status (10)
Country | Link |
---|---|
US (2) | US10392657B2 (en) |
EP (1) | EP2881739B1 (en) |
JP (1) | JP6543253B2 (en) |
KR (1) | KR102275752B1 (en) |
CN (1) | CN106030307B (en) |
CA (1) | CA2932524C (en) |
DK (1) | DK2881739T3 (en) |
ES (1) | ES2637385T3 (en) |
PT (1) | PT2881739T (en) |
WO (1) | WO2015083121A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITTO20120962A1 (en) * | 2012-10-31 | 2014-05-01 | Silicon Biosystems Spa | METHOD AND KIT TO REVEAL A SEQUENCE OF WILD-TYPE AND / OR MUTATE TARGET DNA |
ITUA20162640A1 (en) * | 2016-04-15 | 2017-10-15 | Menarini Silicon Biosystems Spa | METHOD AND KIT FOR THE GENERATION OF DNA LIBRARIES FOR PARALLEL MAXIMUM SEQUENCING |
EP3431611A1 (en) | 2017-07-21 | 2019-01-23 | Menarini Silicon Biosystems S.p.A. | Improved method and kit for the generation of dna libraries for massively parallel sequencing |
IT201900002777A1 (en) * | 2019-02-26 | 2020-08-26 | Menarini Silicon Biosystems Spa | METHOD AND MICROFLUIDIC SYSTEM FOR THE ISOLATION OF PARTICLES |
CN112662748B (en) * | 2019-10-15 | 2023-02-17 | 骏实生物科技(上海)有限公司 | Primer pair combination, method and kit for single cell DNA sequencing library quality identification |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2172353T3 (en) * | 1998-09-18 | 2002-09-16 | Micromet Ag | AMPLIFICATION OF THE DNA OF A SINGLE CELL. |
WO2009051842A2 (en) * | 2007-10-18 | 2009-04-23 | The Johns Hopkins University | Detection of cancer by measuring genomic copy number and strand length in cell-free dna |
EP3722810A3 (en) * | 2009-02-11 | 2021-01-13 | Caris MPI, Inc. | Molecular profiling of tumors |
CN102533960B (en) * | 2010-12-31 | 2014-04-30 | 深圳华大基因科技有限公司 | Single-cell genome analysis method and kit |
-
2013
- 2013-12-04 DK DK13195770.6T patent/DK2881739T3/en active
- 2013-12-04 ES ES13195770.6T patent/ES2637385T3/en active Active
- 2013-12-04 EP EP13195770.6A patent/EP2881739B1/en active Active
- 2013-12-04 PT PT131957706T patent/PT2881739T/en unknown
-
2014
- 2014-12-04 US US15/101,299 patent/US10392657B2/en active Active
- 2014-12-04 KR KR1020167017659A patent/KR102275752B1/en active IP Right Grant
- 2014-12-04 CN CN201480074845.3A patent/CN106030307B/en active Active
- 2014-12-04 WO PCT/IB2014/066602 patent/WO2015083121A1/en active Application Filing
- 2014-12-04 CA CA2932524A patent/CA2932524C/en active Active
- 2014-12-04 JP JP2016536851A patent/JP6543253B2/en active Active
-
2019
- 2019-06-27 US US16/455,470 patent/US20190316194A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
ES2637385T3 (en) | 2017-10-13 |
DK2881739T3 (en) | 2017-08-21 |
US20190316194A1 (en) | 2019-10-17 |
PT2881739T (en) | 2017-08-11 |
KR20160115913A (en) | 2016-10-06 |
EP2881739A1 (en) | 2015-06-10 |
CA2932524A1 (en) | 2015-06-11 |
KR102275752B1 (en) | 2021-07-12 |
JP6543253B2 (en) | 2019-07-10 |
WO2015083121A1 (en) | 2015-06-11 |
JP2016538872A (en) | 2016-12-15 |
CN106030307B (en) | 2018-06-01 |
US20180187254A1 (en) | 2018-07-05 |
CA2932524C (en) | 2022-12-13 |
CN106030307A (en) | 2016-10-12 |
US10392657B2 (en) | 2019-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5843840B2 (en) | New cancer marker | |
Yung et al. | Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non–small cell lung cancer patients | |
US20190316194A1 (en) | Method and kit for determining the genome integrity and/or the quality of a library of dna sequences obtained by deterministic restriction site whole genome amplification | |
EP2218794A1 (en) | Detection of instability in regions of genomic DNA containing simple tandem repeats | |
JP2021513858A (en) | Improved detection of microsatellite instability | |
Stigt et al. | Pyrosequencing analysis of EGFR and KRAS mutations in EUS and EBUS-derived cytologic samples of adenocarcinomas of the lung | |
CN113891943A (en) | Comparative analysis of microsatellites by Capillary Electrophoresis (CE) DNA mapping | |
WO2022157764A1 (en) | Non-invasive cancer detection based on dna methylation changes | |
CA2194696A1 (en) | Method, reagents and kit for diagnosis and targeted screening for retinoblastoma | |
US20190161808A1 (en) | Method for predicting prognosis of breast cancer patients by using gene deletions | |
US20180223367A1 (en) | Assays, methods and compositions for diagnosing cancer | |
Kašubová et al. | Next Generation Sequencing in Molecular Diagnosis of Lynch Syndrome–a Pilot Study Using New Stratification Criteria | |
WO2018186687A1 (en) | Method for determining nucleic acid quality of biological sample | |
KR101644661B1 (en) | Mitochondrial DNA deletion between about residues 12317-16254 for use in the detection of cancer | |
US8828662B2 (en) | Method and kit for detection of microsatellite instability-positive cell | |
KR101723207B1 (en) | Dumbbell-shaped oligonucleotides and method for detecting gene mutation using the same | |
KR102236717B1 (en) | Method of providing the information for predicting of hematologic malignancy prognosis after peripheral blood stem cell transplantation | |
US20090181397A1 (en) | Predictive and diagnostic methods for cancer | |
US7094538B2 (en) | Diagnostic assay for cancer susceptibility | |
Walsh et al. | Molecular pathology in lung cancer: a guide to the techniques used in clinical practice | |
US20080213781A1 (en) | Methods of detecting methylation patterns within a CpG island | |
US20120172242A1 (en) | Cancer specific transcript variants | |
EP2313529A2 (en) | Method for determining reduced predisposition to cancer based on genetic profile | |
Bergfors | Evaluation of Microsatellite Instability Analysis as a Diagnostic Tool to Identify Lynch Syndrome in Endometrial Cancer Patients | |
WO2011073402A1 (en) | Transcript variants of vnn1 and slc39a14 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20131204 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
R17P | Request for examination filed (corrected) |
Effective date: 20151204 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
17Q | First examination report despatched |
Effective date: 20160129 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWAN Owner name: MENARINI SILICON BIOSYSTEMS S.P.A. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20161111 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20170406 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 894930 Country of ref document: AT Kind code of ref document: T Effective date: 20170615 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013021198 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 2881739 Country of ref document: PT Date of ref document: 20170811 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20170804 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20170817 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: HEPP WENGER RYFFEL AG, CH |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20170517 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2637385 Country of ref document: ES Kind code of ref document: T3 Effective date: 20171013 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170818 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170817 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170917 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013021198 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20180220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171204 Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171204 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 894930 Country of ref document: AT Kind code of ref document: T Effective date: 20170517 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20131204 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170517 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230518 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231219 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20231222 Year of fee payment: 11 Ref country code: PT Payment date: 20231128 Year of fee payment: 11 Ref country code: NO Payment date: 20231219 Year of fee payment: 11 Ref country code: NL Payment date: 20231226 Year of fee payment: 11 Ref country code: IT Payment date: 20231127 Year of fee payment: 11 Ref country code: IE Payment date: 20231219 Year of fee payment: 11 Ref country code: FR Payment date: 20231226 Year of fee payment: 11 Ref country code: DK Payment date: 20231222 Year of fee payment: 11 Ref country code: AT Payment date: 20231219 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20231226 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240118 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20231227 Year of fee payment: 11 Ref country code: CH Payment date: 20240102 Year of fee payment: 11 |